Restablecer Contraseña - La Nueva Forma

Inicio
Ingreso
Registro
Acerca de Diabetes
Contenido para usuarios registrados

Innovación en el tratamiento de la diabetes tipo 2

Para restablecer tu contraseña, por favor, introduce a continuación tu dirección de correo electrónico o nombre de usuario.

Only fill in if you are not human

Material exclusivo para profesionales de la salud. Prohibida su re-distribución. Folleto de información al profesional autorizado por el ISP disponible en el siguiente link o escaneando el código QR.

Referencias:

1. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER1: Randomized Clinical Trial Comparing the Efficacy an Safety of oral Semaglutide Monotherapy with placebo in Patients with Type 2 Diabetes. DiabetesCare, 2019 jun 11. pii: dc190749. doi: 10.2337/dc19-0749 2. Rodbarc, Helena W et al. “Oral Semaglutide Versus Empagliflozinin Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.” Diabetes care vol.42,12 (2019): 2272-2281. doi:10.2337dc19-0883 3. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of Additonal Oral semaglutide vs. Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA, 2019 Mar 23. doi: 10.1001/jama.2019 2942. 4. Pratley R, Amod A, Hoff ST, et al. Oral Semaglutideversus subcutaneous Liraglutide and placebo in Type 2 Diabetes (PIONEER 4): A Randomized. double-blind, phase 3a trial. Lancet, 2019 Jun 7. pii: S0140-6736(19)31271-1.doi:10.1016/s0140-6736(19)31271-1 5. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2019 Jun 6. pii:s2213-8587(19)30192-5. doi:10.1016/S2213-8587(19)30192-5. 6. VBain SC, Mosenzon O, Arechavaleta R, et al. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes Obes.Metab. 2019 Mar 21 (3):499-508. doi:10.1111/dom.13553. 7. Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes endocrino. 2019 jun 6. pii: S2213-8587(19)30194-8 8. Bernard Zinmar, Vanit R. Aroda, John B. Buse, Bertrand Cariou, Stewart B. Harris, Soren Tetens hoff, karen Boje Pedersen, Mads Jeppe Tarp-Johansen, Eiichi Araki, PIONEER 8 Investigators; Efficacy and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes : The PIONEER 8 Trial. Diabetes Care 1 December 2019; 42 (12): 2262-2271. http://doi.org/10.2337/dc19-0898 9. Theti TK. Diabetes Obes Metab. 202;22:1263-1277 10. Carls G, Huynh J, Tuttle E. yee J, Edelman SV. Achievement of glycated hemoglobin goals in the IS remains unchanged throughout 2014 . Diabetes Ther. 2017;8(4):863-873 11. Withmore C. Type 2 Diabetes and obesity in Adults. Br J nurs. 201; 19(14):880,882-886. 12. Sorli C et al. Efficacy and Safety once-weekly semaglutide monotherapy versus placebo in patients with type 2 Diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group. multinacional, multicentre phase 3a trial Lancet Diabetes Endocribol 2018;5:251-260. 13. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841-851 14. Carls G, Huynh J, Tuttle E, Yee J, Edelman SV. Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther. 2017;8(4):863-873 15. Whitmore C. Type 2 diabetes and obesity in adults. Br J Nurs. 2010;19(14)880, 882-886. 16. Rybelsus® – Folleto de Información al prof esional autorizado por el ISP.

CL22RYB00020

Cargando...